DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR FELODIPINE
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for Felodipine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00367939 | Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine | Completed | Novartis | Phase 3 | 2005-12-01 | The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in hypertensive patients not responding to treatment with ACE inhibitor plus calcium channel blocker |
| NCT00392262 | A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients | Completed | Novartis | Phase 3 | 2006-08-01 | The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in hypertensive patients not responding to treatment with amlodipine or felodipine alone. |
| NCT00507845 | Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina | Completed | Sanofi | Phase 4 | 2007-06-01 | Primary: - To assess effectiveness of Ramipril-Felodipine in hypertensive Argentinean patients Secondary: - To assess tolerability of Ramipril-Felodipine in hypertensive Argentinean patients. |
| NCT00841880 | China Medical University Hospital (CMUH) Triapin Listing | Completed | Sanofi | Phase 4 | 2009-01-01 | The objective of this study is to compare the reduction in office seated systolic blood pressure (BP) following a 8 weeks regimen of ramipril 5mg plus felodipine 5mg versus ramipril 10mg. To compare the response rate (defined as office systolic blood pressure (SBP) / Diastolic blood pressure (DBP) reduce more than 10mmHg from baseline), and BP controlled rate (defined as SBP<140mmHg and/or DBP<90mmHg) and as SBP < 130 mmHg and /or DBP < 80 mmHg in diabetes,chronic kidney disease, known Coronary Arterial Disease (CAD) or CAD equivalent, or 10-year Framingham risk score > 10%. To ascertain the safety and tolerability of ramipril/felodipine versus ramipril in Taiwanese population. To compare compliance with fixed dose combination of ramipril/felodipine versus ramipril treatment. |
| NCT00905333 | Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal | Completed | Clínica São Lucas, Hospital Sírio Libanês de Itatiba S/C | Phase 1 | 2008-10-01 | The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations of candesartan and felodipine in a combination package comparing with the fasting intake of commercial formulations of both Atacand ® and Splendil® |
| NCT00905333 | Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal | Completed | Cori Analyticals | Phase 1 | 2008-10-01 | The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations of candesartan and felodipine in a combination package comparing with the fasting intake of commercial formulations of both Atacand ® and Splendil® |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Felodipine
Condition Name
Clinical Trial Locations for Felodipine
Clinical Trial Progress for Felodipine
Clinical Trial Phase
Clinical Trial Sponsors for Felodipine
Sponsor Name
